Vaso Occlusive crisis Associated with Sickle Cell Disease Market
Global Vaso Occlusive crisis Associated with Sickle Cell Disease Market Size, Share & Trends Report by Type (Crizanlizumab, SGD-2083, NVX-508, PF-04447943, and Others) and by Application (Hospital, Clinics, and Others) Forecast( 2022-2028) Update Available - Forecast 2024-2030
The global vaso occlusive crisis associated with the sickle cell disease market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). The vaso occlusive crisis occurs when the circulation of blood is obstructed by sickled red blood cells causing pain. The rise in the prevalence of anemia is one of the major factors driving the growth of the market. For instance, according to the data published by World Health Organization, in 2019, the prevalence of anemia was around 29.9% in women aged between 15-49 years. Additionally, according to WHO, in 2019, the prevalence of anemia was 39.8% in children aged between 6-59 months. The prevalence of anemia in children under 5 years was highest in the African region. Moreover, according to National Center for Biotechnology Information (NCBI), the prevalence of anemia increases with advancing age, and rises up to 20 % in those 85 years and older. Thus, the rise in the prevalence of anemia is one of the major drivers in boosting the growth of the market over the forecast period.
Impact of COVID-19 Pandemic on Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market
The COVID-19 pandemic resulted in a significant impact on the Global Vaso Occlusive crisis associated with Sickle Cell Disease Market. The pandemic has resulted in a decline in the number of donors, owing to the unwillingness of people to visit the healthcare facilities due to restrictions. Also, due to the rising prevalence of COVID-19 cases, government organizations and healthcare facilities have postponed the non-elective surgeries to reallocate the resources to manage COVID-19 patients. Thus, lockdowns and restrictions have resulted in a significant impact on the global vaso occlusive crisis associated with the sickle cell disease market.
Segmental Outlook
The global vaso occlusive crisis associated with the sickle cell disease market is segmented based on type and application. Based on the type, the market is further sub-segmented into Crizanlizumab, SGD-2083, NVX-508, PF-04447943, and Others. Based on application, the market is further sub-segmented into hospitals and clinics. Among these, the hospital segment is anticipated to hold a considerable share in the market owing to the increase in the number of emergency room visits.?
Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market by Type, 2021 (%)
The Crizanlizumab is Anticipated to Hold a Prominent Share in the Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market
The Crizanlizumab is a monoclonal antibody medication that reduces the vaso-occlusive crisis in people aged 16 years and older who suffer from sickle cell anemia. The rise in sickle cell disease is one of the major drivers in boosting the growth of the crizanlizumab drug. For instance, according to the Center for Disease Control (CDC), sickle cell disease is commonly found in ancestors who originated from Saharan Africa. Moreover, according to CDC in 2020, around 100000 Americans are affected by sickle cell disease. Also, 1 out of 365 African births is affected by sickle cell disease. Thus, owing to the rising prevalence of sickle cell disease, the crizanlizumab drug is anticipated to grow at a significant rate over the forecast period.
Regional Outlook
The global vaso occlusive crisis associated with the sickle cell disease market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these North, America segment is anticipated to hold a considerable share in the market owing to the rise in healthcare infrastructure and medical insurances.
Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market, by Region 2022-2028
Africa, Middle East, Latin America, and Mediterranean regions are Estimated to Hold Major Share in Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market.
Increasing investment on medical care facilities and public health care is anticipated to increase the number of patients associated with sickle cell diseases. According to the health experts and representatives of human rights organization, the lack of investments in infrastructure and medical equipment have made it harder for African nations to retain skilled healthcare professionals and to reduce the mortality rate of perineal diseases. Moreover, in 2020, according to the Cross-Sectional Population survey and cohort studies of SCD in Africa, 50 to 90% of SCA children died before age 5 years. Thus, the increased awareness and investment on healthcare infrastructure facilities offers an opportunity to the market which in turn is boosting the of the global vaso occlusive pain crisis associated with the sickle cell disease market.
Market players Outlook
The major companies serving the global sickle cell disease market are Novartis AG, AstraZeneca Plc., Medunik USA Inc., Bristol-Myers Squibb Co, Emmaus Medical Inc., and more among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2019, the US Food and Drug Administration has approved Adakveo (crizanlizumab). The adakveo is a monoclonal antibody medication, which reduces the frequency of vaso occlusive crisis in adults aged 16 years and older suffering from sickle cell disease.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global vaso occlusive crisis associated with the sickle cell disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market
- Recovery Scenario of The Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. AstraZeneca Plc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Bristol-Myers Squibb Co.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Emmaus Medical Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Medunik USA Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Novartis AG
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market by Type
4.1.1. Crizanlizumab
4.1.2. SGD-2083
4.1.3. NVX-508
4.1.4. PF-04447943
4.2. Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market by Application
4.2.1. Clinics
4.2.2. Hospitals
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Alnylam Pharmaceuticals, Inc.
6.2. Arena Pharmaceuticals, Inc
6.3. Acceleron Pharma, Inc. (Merck &Co.)
6.4. Bluebird bio, Inc.
6.5. Baxter International, Inc.
6.6. Daiichi Sankyo Co.
6.7. Dr.Reddy’s Laboratories, Ltd.
6.8. Eli Lilly &Co.
6.9. Global Blood Therapeutics, Inc.
6.10. Johnson & Johnson Services, Inc.
6.11. SANOFI
6.12. Sangamo Therapeutics, Inc.
6.13. Takeda Pharmacuetical Co, Ltd.
6.14. Teva Pharmaceutical Industries Ltd.
1. GLOBAL VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL CRIZANLIZUMAB VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL SGD-2083 IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL NVX-508 IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL PF-04447943 IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
7. GLOBAL CLINICS IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL HOSPITALS IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
12. NORTH AMERICAN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
13. EUROPEAN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. EUROPEAN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. EUROPEAN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC END STAGE KIDNEY DISEASE TYPE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE 2021-2028 ($ MILLION)
18. ASIA-PACIFIC END STAGE KIDNEY DISEASE TYPE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. REST OF THE WORLD VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. REST OF THE WORLD VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. REST OF THE WORLD VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET, 2021-2028 (%)
4. GLOBAL VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SHARE BY TYPE, 2021VS 2028 (%)
5. GLOBAL CRIZANLIZUMAB IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
6. GLOBAL SGD-2083 IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
7. GLOBAL NVX-508 IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL PF-04447943 IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SHARE BY APPLICATION, 2021VS 2028 (%)
10. GLOBAL CLINICS IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
11. GLOBAL HOSPITALS IN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
12. US VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
13. CANADA VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
14. UK VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
15. FRANCE VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
16. GERMANY VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
17. ITALY VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
18. SPAIN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
19. REST OF EUROPE VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
20. INDIA VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
21. CHINA VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
22. JAPAN VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
23. SOUTH KOREA VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF ASIA-PACIFIC VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF THE WORLD VASO OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE MARKET SIZE, 2021-2028 ($ MILLION)
